Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued [Seeking Alpha]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Seeking Alpha
2026 guidance targets $5.1bn–$5.5bn revenue, ~38% growth, and operating profit potentially near $1.8bn, positioning ALNY closer to Big Pharma metrics. Pipeline progress includes next-gen TTR therapies, hypertension, and gMG assets, but pivotal data for most assets remain outstanding. I maintain a Hold rating due to intense ATTR-CM competition, pipeline execution risks, and anticipated volatility ahead of key catalysts. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » DjelicS/E+ via Getty Images Investment Overview In my last note on Alnylam Pharmaceuticals ( ALNY ) for Seeking Alpha published at the end of October last year, I assigned the RNA-interference specialist drug developer's stock a Hold rating. I discussed how the RNA-i space had been More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and hea
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial [Yahoo! Finance]Yahoo! Finance
- CureVac sues Moderna for patent infringement over COVID-19 vaccines [Yahoo! Finance]Yahoo! Finance
- CureVac sues Moderna for patent infringement over COVID-19 vaccines [Yahoo! Finance Canada]Yahoo! Finance Canada
- BXMT Q2 2025 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/7/26 - Form 4
- 4/7/26 - Form 3
- ALNY's page on the SEC website